Latest Hotspot

FDA Approves First T-Cell Engager Therapy for Extensive-Stage Small Cell Lung Cancer

21 May 2024
3 min read

Amgen revealed that IMDELLTRA™ (tarlatamab-dlle) has received approval from the U.S. Food and Drug Administration for use in adult patients experiencing disease progression in extensive-stage small cell lung cancer following platinum-based chemotherapy.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

IMDELLTRA has been granted accelerated approval due to the promising response rate and duration observed in clinical trials. Ongoing approval for this use might depend on the confirmation and detailed analysis of clinical benefits in a confirmatory study.

"The FDA's approval of IMDELLTRA is a significant breakthrough for patients struggling with ES-SCLC. This DLL3-targeting therapy for ES-SCLC offers a groundbreaking option that shows enduring responses in pretreated patients," stated Jay Bradner, M.D., executive vice president of Research and Development and chief scientific officer at Amgen.

"This approval underscores our dedication to tackling aggressive cancers through our second FDA-approved Bispecific T-cell Engager molecule. IMDELLTRA provides hope to these patients in dire need of novel therapies, and we take pride in delivering this much-anticipated effective treatment to them," Jay Bradner continued.

"Lung cancer is a complex and devastating condition, with less than 3% of individuals with ES-SCLC surviving beyond five years," said David P. Carbone, M.D., Ph.D., professor of internal medicine and director of the James Thoracic Oncology Center at Ohio State University Medical Center. "In the DeLLphi-301 trial, the median overall survival was 14.3 months, with 40% of patients responding to treatment with tarlatamab. These durable responses signify a major advancement in the SCLC treatment paradigm."

IMDELLTRA is the first DLL3-targeting Bispecific T-cell Engager therapy that activates the patient’s T cells to attack DLL3-expressing tumor cells.

"Following decades of minimal progress in the SCLC treatment landscape, an effective and innovative treatment option is now accessible," noted Laurie Fenton Ambrose, co-founder, president, and CEO of GO2 for Lung Cancer. “Today’s FDA approval is a critical milestone for the SCLC community, as the availability of a targeted bispecific therapy introduces new possibilities for those suffering from this aggressive disease.”

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of May 20, 2024, there are 16 investigational drugs for the CD3 and DLL3 target, including 13 indications, 16 R&D institutions involved, with related clinical trials reaching 30, and as many as 2281 patents.

TARLATAMAB-DLLE targets CD3 x DLL3 and is indicated for the treatment of neoplasms, respiratory diseases, and urogenital diseases. Its active indications include extensive stage small cell lung cancer, advanced lung small cell carcinoma, small cell lung cancer, and prostate neuroendocrine carcinoma.

图形用户界面, 文本, 网站

描述已自动生成

Johnson & Johnson to Purchase Proteologix, Inc. to Lead in Eczema Treatment
Latest Hotspot
3 min read
Johnson & Johnson to Purchase Proteologix, Inc. to Lead in Eczema Treatment
21 May 2024
Proteologix’s lineup includes PX128, a bispecific antibody that targets both IL-13 plus TSLP. PX128 is poised to advance into phase 1 development for the treatment of moderate to severe atopic dermatitis and asthma.
Read →
Bayer Starts Phase I Trial of 225Ac-PSMA Targeted Therapy for Advanced Prostate Cancer
Latest Hotspot
3 min read
Bayer Starts Phase I Trial of 225Ac-PSMA Targeted Therapy for Advanced Prostate Cancer
21 May 2024
Bayer Begins Phase I Trial of 225Ac-PSMA-Trillium Targeted Radionuclide Therapy for Advanced Metastatic Prostate Cancer.
Read →
FDA Approves Breyanzi for Relapsed/Refractory Follicular Lymphoma
Latest Hotspot
3 min read
FDA Approves Breyanzi for Relapsed/Refractory Follicular Lymphoma
21 May 2024
The U.S. FDA has approved Bristol Myers Squibb's CAR T cell therapy Breyanzi for treating relapsed or refractory follicular lymphoma.
Read →
Genentech Reports Positive Phase Ib Results for Obesity Drug CT-388
Latest Hotspot
4 min read
Genentech Reports Positive Phase Ib Results for Obesity Drug CT-388
21 May 2024
Genentech Announces Favorable Phase Ib Outcomes for Dual GLP-1/GIP Receptor Agonist CT-388 in Obesity Patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.